LCLAT1 and obesity disorder: ,56,58 Ablation or pharmacological inhibition of LCLAT1 prevented mitochondrial dysfunction by restoring non-pathological CL profiles, improving mitochondrial ETC activity, suppressing Drp1 activation, and preventing the onset of obesity, type2 diabetes, myocardial infarction, fatty liver disease, and neurological diseases, as reviewed in Ref.32